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ABSTRACT 
Loss of nerve cells and axons is a common feature of common complex 
neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. However, 
also Multiple Sclerosis (MS), primarily an autoimmune disorder, has a prominent 
neurodegenerative component. In complex disorders, many components affecting 
disease development and disease progression in combination make up the overall risk. 
In general, we divide these factors into inherited genetic factors and environmental 
factors. In addition, there are sometimes complex gene-environment interactions that 
make it difficult to identify individual risk components. 
 
In this thesis, I have focused on a translational approach to find genetic determinants of 
nerve cell survival in a simplified experimental model of nerve injury-induced 
neurodegeneration. The aim has been to find novel genes/pathways whose relevance 
subsequently can be tested in human disease. Through various genetic mapping 
approaches I demonstrate a strong inverse correlation between neuronal survival and 
expression and protein levels of an enzyme involved in detoxification of certain 
oxidation by-products. This enzyme, Glutathione S-Transferase alpha 4 (Gsta4), is 
highly efficient in catalysing the reduction of the neurotoxic aldehyde 4-
hydroxynonenal (HNE), which is generated during lipid peroxidation and has 
previously been implicated in the pathogenesis of various neurodegenerative disorders. 
 
The relevance of this mechanism was also tested in a model of traumatic brain injury, 
where Gsta4 levels inversely correlate with degree of neuronal loss as well. In addition, 
rats with higher Gsta4 levels have a more favourable outcome after injection of HNE 
directly into the cortex. Taken together, these two studies provide strong support for the 
notion that the identified pathway is highly important for ability to cope with oxidative 
stress and in turn of relevance for nerve cell survival in different types of acute injury. 
 
Finally, a possible role for Gsta4 is tested in experimental autoimmune 
encephalomyelitis (EAE), a model of MS. No discernible clinical effect was observed 
between congenic rats with higher Gsta4 expression and the parental strain. However, 
lower Gsta4 expression was associated with a stronger autoantibody response. Protein 
modifications by HNE have in other inflammatory models been documented to induce 
a stronger antibody response, which is consistent with the obtained results. Intrathecal 
antibody production is an important diagnostic marker in MS, and hypothetically the 
HNE pathway can play a role for disease course through both neurotoxicity and 
amplification of the immune response. This was tested in a large case control cohort of 
MS, where suggested associations both to clinical and immune phenotypes were found. 
In summary, the results presented encourage further studies on the Gsta4-HNE pathway 
both in conditions of acute nerve injury and autoimmune neuroinflammation. 
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
De flesta har nog upplevt vad som händer med olja som blivit stående lite för länge 
hemma i köket; den härsknar. Den process som huvudsakligen ligger bakom detta är 
lipidperoxidering, d.v.s att fetterna reagerar med syre. Om man sticker ned en kvist 
rosmarin blir det inte bara gott, utan det förhindrar också att oljan härsknar. Rosmarin 
innehåller ovanligt stora mängder av särskilda molekyler som binder upp reaktiv syre 
och förhindrar reaktion med oljan; antioxidanter. 
 
Kroppens celler använder syre för att tillgodogöra sig energi och innehåller dessutom 
stora mängder lipider, vilket gör dem känsliga för lipidperoxidering. Cellerna har därför 
utvecklat olika sätt att skydda sig, bland annat genom att likt rosmarinoljan innahålla 
antioxidanter som kan neutralisera oxidanterna och därmed förhindrar att dessa reagerar 
med andra molekyler. Dessutom kan denna process ske än mer effektivt genom att det 
finns särskilda enzymer som katalyserar reaktionerna och förbättrar skyddet. Det 
centrala nervsystemet är särskilt känsligt för lipidperoxidering genom sitt höga 
syrebehov i kombination med ett högt fettinnehåll. Hjärnan, som endast upptar cirka 
2% av kroppsvikten, konsumerar ändå 20% av allt syre i kroppen under vila. 
Nervcellerna har dessutom ett extra stort behov av att skyddas från skadliga effekter av 
lipidperoxidering eftersom de i princip inte alls kan nybildas. 
 
Bakgruden till detta avhandlingsarbete var observationen att två olika stammar av 
inavlade laboratorieråttor uppvisar en stor variation i antal överlevande nervceller efter 
en standardiserad nervskada under kontrollerade miljöbetingelser, vilket indikerar en 
ärftlig reglering av nervcellernas känslighet. Genom att i en första studie definiera ett 
genområde som styr denna skillnad och sedan i ett uppföljande arbete med olika 
experimentella metoder identifiera en enskild gen i området kan vi här visa på ett 
samband mellan enzymet Gsta4, som katalyserar oskadliggörandet av reaktiva 
biprodukter av lipidperoxidering, och nervcellsöverlevnad. Dessa reaktiva biprodukter 
har påvisats i flertalet kroniska neurodegenerativa sjukdomar, men även vid akuta 
tillstånd som traumatisk hjärnskada. Det tredje arbetet visar att samma ärftliga variation 
i Gsta4 påverkar nervcellsdöd även efter experimentell hjärnskada.  
 
Slutligen, i avhandlingens fjärde arbete, visas att ärftligt betingad variation i Gsta4 
också påverkar det immunolgiska svaret i en modell för sjukdomen MS och att en 
liknande variation även kan föreligga hos människa. Sammantaget understryker de 
resultat som här presenteras betydelsen av oxidativ stress och lipidperoxidering vid 
olika sjukdomstillstånd i nervsystemet och identifierar ett enskilt protein, Gsta4, vars 
funktion är ärftligt reglerad och som påverkar nervcellsdöd. Vidare studier behövs för 
att i detalj kartlägga betydelsen av ärftlig variablitet i GSTA4 för olika former av 
neurodegenerativa sjukdomar hos människor. 
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1 AIMS OF THIS THESIS 
 
The aims of these thesis was to investigate a previously identified gene region in the rat 
that was shown to affect the degree of neuronal survival after nerve injury, in order to 
find the underlying gene(s) and pin point a relevant mechanism. Further, to use a 
translational approach to explore whether this mechanism is relevant in other models 
and in human disease. 
 
In detail, the aim for the different studies was: 
 
Paper I:  To reproduce and fine map the previous linkage to nerve cell death after 
nerve injury in advanced intercross lines. Further, to prove the effect of the 
linked region by the use of congenic strains. 
 
Paper II: To position a likely candidate gene among the remaining genes in the fine 
mapped genomic region. 
 
Paper III: To explore if the identified genetic effect is of relevance also in other models 
of neurodegeneration and, if so, dissect underlying mechanisms more in 
detail.  
 
Paper IV: To explore if the identified genetic variation affects outcome in experimental 
autoimmune encephalomyelitis and its model disease, multiple sclerosis. 
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2 GENETICS OF COMPLEX DISEASE 
 
2.1 OVERVIEW 
The first diseases in which causing gene variants were discovered were so called 
monogenic, or mendelian, disorders where a single gene variant causes disease. 
Examples of diseases linked to monogenic traits include haemophilia, cystic fibrosis, 
sickle cell anaemia and Huntington’s disease. However, monogenic diseases are overall 
rare, although the number of different monogenic traits is large. Today approximately 
3000 gene variants have so far been detected and these are suggested to make up 30-
50% of all suspected mendelian disorders [1]. However, more common is a polygenic 
nature of disease, where a number of gene variants are involved in the pathogenesis and 
where each gene gives a small contribution to total disease risk.  
 
A majority of the polygenic disorders are further likely to be associated with known or 
yet unknown environmental factors, that adds to risk or interact with the genetic factors, 
so called gene-environment interactions. These diseases are referred to as complex 
diseases, where gene variants that increase the risk are called predisposing genes. 
Predisposing gene variants generally only slightly increase the risk to develop a certain 
disease and therefore the variants also frequently occur in the healthy population. A 
certain gene variant can also be predisposing for one disease, but protective in other 
settings. There are for example studies that indicate that positive selection for genes 
involved in immune response to pathogens, protective for infectious diseases, that in 
the past was extremely favourable and positively selected, today turn out as risk genes 
for autoimmune disease [2]. Further, alleles that are defined as risk alleles in one 
autoimmune disease may be protective in another [3]. These factors result in that not 
only the disorders are complex, but also the genetic dissection of them. 
 
 
2.2 THE THRESHOLD MODEL 
The threshold model in a complex disease refers to the multifactorial predisposing 
factors that together add risk. Taken together, all these factors might result in that the 
total disease risk reaches above a level where disease is elicited. A low influence from 
predisposing genes might still result in disease development is there is a strong 
influence of environmental factors and vice versa. This is schematically depicted in 
figure 1. However, this picture is two dimensional and shows a purely additive 
scenario. More likely, 1+1≠2 and a combination of a certain genetic and environmental, 
or several genetic factors, might give a much higher total contribution than each 
contributing factor alone. 
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The main non genetic risk factor for neurodegenerative disorders, that seems to be 
common to almost all diseases, is increased age. Extremely generalized, early onset of 
neurodegenerative disorders seems to have a stronger genetic component, while late 
onset cases have less genetic influence and likely more influence from other factors. 
Early onset cases are more likely to occur in families, so called familiar cases, while 
late onset cases are more likely to be sporadic. Since neurons of the CNS do not renew, 
at least not to a large extent, and some loss over time is unavoidable there is a slow 
progression towards disease. However, under favourable conditions the slope is so low 
that disease will not be developed. However, early or continuous environmental 
exposure and/or genetic predisposition can lower the distance to disease, change the 
slope towards disease progression etc. (figure 1). 
 
 
 
 
Figure1: The threshold model for developing complex disease, where the total disease burden 
of several genetic and environmental factors add on top of each other with individual pattern, 
and lead to disease development if the threshold level for total risk is exceeded (left). 
Environmental contribution will be added over time, and so also effect of genetic variation that 
might only have effect in the presence of certain environmental factors. Increased age is always 
a risk factor for neurodegenerative disorders, but without other factors disease will not develop 
[1] (right). Genetic factors, like lower capacity to reduce varying toxic molecules, might give a 
steeper slope under the same environmental exposure and lead to earlier disease development 
[2].Certain factors, genetic or environmental, early in life can result in a lower spare capacity 
and disease development earlier in life [3].  
 
 
2.3 GENETIC DISSECTION 
A main challenge in genetic dissection of complex disease is that predisposing gene 
variant that only slightly contributes to increased disease risk frequently occurs also in 
the healthy population. The gene variant is said to have low penetrance. In addition, 
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contributions from a large number of rare genetic variants in the population might 
significantly affect risk at individual level, but have low relevance on population level. 
A given question based on these facts is if there actually is of any value to study 
genetics of complex diseases? 
 
However, there are many reasons why genetic dissection of complex disorders is 
important. First of all, increased knowledge about risk factors can point out certain 
common molecular pathways of importance for disease, although different genes and 
variations might underlie the pathway changes. Drug development can focus on 
targeting the pathway rather than individual genes. Second, certain gene variants might 
reflect sub-phenotypes of the disease and also predict disease course and severity. This 
could be of importance at individual level for developing individually adjusted 
treatment. With a predicted aggressive disease course, a more efficacious treatment 
with more side effects might be acceptable than with a predicted milder disease course. 
 
Knowledge about risk factors at individual level could also be used in preventive 
treatment or in order to actively avoid known environmental factors to reduce the risk 
of reaching above the threshold level, or extend the time before development of 
symptoms. There are already companies where a person can screen his/her genome for 
known predisposing genetic variants of common disorders and get advice from medical 
expertise on how to reduce the risk of developing these. This type of strategy can likely 
be successful in reducing disease prevalence in the future with better knowledge of 
disease aetiology, but at the same time raise many ethical questions of social and 
society aspects, which are necessary to discuss but will not be specifically dealt with 
here. 
 
 
2.4 A TRANSLATIONAL APPROACH 
This study primary looks at neuronal survival after induced mechanical injury in the rat. 
The final goal of this type of research is of course not to cure injured rats, but to find 
mechanisms of general relevance for neurodegeneration that can be translated into 
human disease. This type of translational research in animal models have been widely 
used and have improved our knowledge about several important disease mechanisms 
such as Cd36 in insulin resistance [4], Ncf1 and ZAP-70 in arthritis [5, 6], CTLA-4 in 
diabetes [7] and C5 in liver fibrogenesis [8] but also generated basic understanding of 
biological functions as iron uptake in red blood cells [9]. 
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The study design in this thesis is based on a forward genetics approach, where an 
observed trait is studied in genetic context to identify the underlying variation and 
thereby generate an hypothesis for disease mechanism. This is in contrast to hypothesis 
driven research where the starting point is a suggested gene and mechanism which is 
manipulated and tested for phenotypic effect.  
 
Hypothesis driven genetic research for candidate genes for human disorders have the 
disadvantage that the hypothesis has to be generated based on previous observations 
and therefore is less likely to identify novel mechanisms. A widely used unbiased 
approach is screens in large materials that cover the whole genome (GWAS, later 
described). However, a disadvantage here is the number of tests utilized, raising the 
threshold level for significance. The translational approach in genetic dissection 
combine the unbiased genetic screening with the hypothesis driven approach by testing 
identified hypothesis/candidate genes from unbiased animal studies in human disease. 
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3 NEURODEGENERATIVE DISORDERS 
 
Genetics plays an important role in neurodegenerative disorders. There are examples of 
genetic variations that directly lead to disease (monogenic), but also likely a large effect 
on disease development and severity in complex disorders. The following section aims 
to give a brief overview about in different disease with a neurodegenerative component 
and current knowledge of the role of genetic background for disease development. 
 
 
3.1 PRIMARY DEGENERATIVE DISORDERS 
Huntington's disease (HD) is characterized by uncontrolled excessive motor 
movements, named chorea, and cognitive and emotional deficits. It was first described 
and named after George Huntington who published a paper that described the disease in 
1872 [10]. Onset is typically seen in middle age, but can start at any age from infancy 
to old age and the disease is neuropathologically characterized by neurodegeneration in 
selective parts of the brain. HD has a dominant mendelian inheritance and was linked to 
an unstable triplet repeat expansion of a gene later named Huntingtin in 1993 [11]. The 
CAG expansion gives rise to a chain of extra glutamine amino acids in the protein, 
called PolyQ. The number of extra repeats largely affects the disease onset and account 
for approximately 60% of variance. 35 repeats or less is not associated with disease, 
while 36-40 shows incomplete penetrance [12] A common pathological pattern with 
many of the neurodegenerative disorders is formation of protein aggregates, here with 
mutant HTT and polyQ. However, studies implicate that the aggregates are not 
neurotoxic but rather that the mutant protein is in a dose dependent way [13]. 
 
Alzheimer's disease (AD) was first described in 1906 by the German pathologist Alois 
Alzheimer. He classified it as a rare disease with dementia mainly in people under 65. 
In 1976 Robert Katzman reclassified the disease with the findings that senile dementia 
in people over 65 in many cases share the same characteristics as previously observed 
in Alzheimer’s [14]. Still today, the age of 65 is used as discriminating the two forms 
early onset and late onset AD (EOAD and LOAD). Alzheimer’s disease is today the 
most common cause of dementia and approximately 26.6 million people had the 
disease in 2006 and it is further estimated to increase 4-fold by 2050 meaning that 1 
person of 85 would live with the disease [15]. The disease is characterized by 
progressive loss of neurons in several brain regions. Histopathology shows intracellular 
formation of neurofibrillary tangles (NFT) made up of abnormally phosphorylated Tau 
protein together with formation of extracellular senile placks consisting of aggregations 
of misfolded amyloid-β (Aβ). The cause of the disease is still unknown but there is a 
strong genetic component in AD. Among early onset AD, linkage analysis in families 
has revealed linkage to rare mutations in the genes encoding APP [16], presenilin-1 
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(PSEN1) [17], and presenilin-2 (PSEN2) [18]. However, also in the later onset sporadic 
cases there is a strong genetic component and it is estimated that genetic components 
account for approximately 60-80% of the attributable risk [19]. There has been 19 
GWAS studies conducted on AD and between 2007 and 2011 according to 
www.alzgene.org [20]. The strongest association, detected in all studies is to the 
apolipoprotein E (APOE) ε4 allele, which has been attributed to up to 30% of the risk 
of LOAD [21]. However, of all other genes detected in different studies, only four other 
can be considered as confirmed by the number of replications, which are Bridging 
integrator 1 (BIN1), Clusterin (CLU), Complement Component receptor 1 (Cr1) and 
Phosphatidylinositol-binding clathrin assembly protein (PICALM) which all are related 
to production, aggregation or clearance of Aβ [22]. 
 
Parkinson's disease (PD) was described in 1817 by James Parkinson and the syndrome 
was later named after him. Although 200 years have passed, the cause of the disease is 
still unknown. The major and strong risk factor is age, with a steady increase in risk 
after the age of 60 [23]. There is no difference in risk between ethnic groups and the 
vast majority of cases are sporadic. In PD a specific group of neurons, dopaminergic 
nigrostriatal neurons, are progressively lost leading mainly to moving deficits. 
Neuronal loss is seen together with formation of intraneuronal Lewy bodies, which are 
aggregates of an abnormal form of the α-synuclein protein. There is still no established 
causative environmental factor although exposure to several pesticides that induce 
oxidative stress has been associated with increased risk [24] while smoking, in a variety 
of diseases regarded as a risk factor, is potentially protective as well as is caffeine 
(reviewed by [25]). Twin studies have indicated that early onset PD have a stronger 
genetic influence than late onset, which likely is more influenced by environmental 
factors [26]. Early onset PD can be linked to rare monogenic mutations, but accounts 
for only 5-10 % of the cases [27]. 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that preferentially 
affects motoneurons in the spinal cord, brain stem and motor cortex. It was originally 
characterized and named by Jean-Martin Charcot 1874, although studies of symptoms 
and pathological changes had been presented by many others since at least 1830 [28]. It 
is a complex and heterogeneous disease with unknown cause and the pathogenesis is 
not fully understood. However, it includes inflammation and release of pro-
inflammatory cytokines from microglia and astrocytes, as well as oxidative stress. ALS 
is often divided into familial ALS (FALS) and sporadic ALS (SALS). Approximately 
5-10% of cases are familial and today there are 18 genes associated to this form where 
SOD1, important for oxidant defence, is the most well-known and accounts for 
approximately 20% of the FALS cases [29]. It also accounts for a few per cent of the 
sporadic cases, and in total 164 different mutations has been found in the gene of ALS 
patients [30]. Possibly, the genetic predisposition of FALS is stronger than expected 
due to low disease penetrance [31]. There are two main hypothesis in how mutant 
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SOD1 affects neurodegeration: either through altered redox reactions or by toxicity of 
the mutant protein itself, since aggregates of mutant SOD1 is found in inclusions both 
in ALS and in disease models [32]. 
 
ALS more commonly affects men than women, but has an almost uniform distribution 
over the world, with one exception; Guam where it is 100-times more common. 
Genetic studies have not been able to find an explanation to this increase, thus focusing 
interest into environmental factors. For a long time, the neurotoxic amino-acid BMAA, 
which is produced by Cyanobacteria and found in cycad seeds commonly found and 
used at Guam, has been suggested to play a role for development of ALS and also other 
neurodegenerative disorders [33]. In contrast to most other disorders, slimness with low 
BMI and high degree of exercise (athletes) seem to be risk factors to develop disease 
[34]. An Italian study has pinpointed professional soccer players at being of particularly 
high risk [35, 36]. However, data has to my knowledge not been reproduced in other 
professional sport leagues.  
 
 
3.2 TRAUMATIC BRAIN INJURY 
Traumatic brain injury (TBI) is the leading cause of death and neurologic disability in 
young individuals in developed countries. Genetics of TBI differ from the above 
mentioned disorders in that there is no direct effect of genetics on disease onset, 
although it could be argued that genetic factors influencing behaviour could be a risk 
factor. The clinical spectrum of TBI is wide and obviously the most important factor 
affecting outcome is the type of trauma, which range from mild concussion to large 
hematomas: almost no injury is exactly similar to another. However, not only the type 
of injury affects outcome, but also gender and age are important factors [37-39]. 
Actually, a main established non genetic risk factor for poor outcome in TBI is 
advanced age. 
 
Nerve cell death after TBI can be divided into primary damage directly caused by the 
trauma and secondary delayed damage that lead to additional neuronal degeneration. 
Secondary neurodegeneration is a process that can be on going for weeks to years after 
the injury. Rapid stabilization of vital functions is important to reduce secondary 
degeneration and improve repair. Hypoxia after TBI has been shown to increase the 
degree of neurodegeneration [40]. The molecular mechanism of secondary 
degeneration is not fully understood but pathophysiological processes like 
excitotoxicity, inflammation, apoptosis, oxidative stress and oedema formation seem to 
play a major role in the delayed neuronal death. From studies in other diseases where 
the same pathways are activated we know these pathways can be genetically regulated. 
Hence, it seems reasonable to hypothesize that inter-individual variation in secondary 
degeneration is likely to at least to some extent be genetically regulated. Although 
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extensive research has been conducted with many clinical trials in the field, there is still 
no efficient treatment to reduce secondary degeneration. 
 
Little is known about genetics of SND severity after TBI, but APOE ε4, previously 
described as a risk gene for AD, has also been associated with worse outcome of TBI 
[41, 42]. In a large number of studies TBI has also been identified as a risk factor for 
later development of AD [43]. This is also the case in stroke, where SND plays an 
important role for cognitive decline and also this process resembles many molecular 
characteristics of AD [44]. The notion that a TBI earlier in life increase risk of AD 
reflects the theory of the threshold model, where TBI likely is a strong environmental 
factor adding risk and reduce the time span for developing (figure 1).  
 
 
3.3 MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is a complex autoimmune disorder, which is characterized by 
chronic inflammation where the immune system attacks the myelin and 
oligodendrocytes that make up the myelin sheets around the axons in the CNS. In 
parallel, or as a consequence of demyelination, axons are damaged leading to disruption 
of neuronal signalling. The symptoms of MS varies widely depending on which signals 
are disrupted but typically includes muscle weakness, sensory and balance disturbance, 
visual problems and cognitive impairment. 
  
An important diagnostic marker in MS is the presence of intrathecal antibody 
production. This is defined as presence of antibodies in the CSF that are uniquely 
synthetized by CNS resident B-cells. There are two measurements of intrathecal 
antibody production, presence of so called oligoclonal bands (OCB) and IgG-index. 
Presence of OCBs is defined as immunoglobulin bands identified by isoelectric 
focusing that uniquely exist in the CSF and not in plasma. IgG-index is a quantitative 
measure of IgG-levels where the index represents a quote between IgG in CSF versus 
serum that is normalized against the same albumin quote, thereby adjusting for barrier 
damage [45]. OCBs are present in approximately 95% of MS patients and a majority, 
70%, also display elevated IgG index [46, 47]. 
 
MS was first described as an independent neurological disease by Jean-Martin Charcot 
in 1868, called sclerose en plaques[48]. Since then, the cause of MS has been a focus 
for many studies with numerous theories being put forward, many of which involves 
the effect of certain toxins or infectious agents. However, no single causative factor of 
this type has been unequivocally shown to induce MS. As an alternative explanation, in 
the 1930s Thomas Rivers showed that MS like disease was developed by injecting 
laboratory animals with myelin, thereby supporting the notion that MS might be an 
autoimmune disease where loss of tolerance lead to an attack by the own immune 
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system to myelin [49, 50]. What remains unknown in MS is the cause of the loss of 
tolerance, and viruses are still today considered a possible contributory factor, with 
special focus on Epstein Barr Virus [51]. Other suggested environmental triggers with 
support from larger studies are low vitamin-D levels and smoking [52]. 
 
The disease course of MS is generally classified into four different sub-types: 
relapsing-remitting MS (RRMS), primary progressive MS (PPMS), secondary 
progressive MS (SPMS) and progressive relapsing MS (illustrated in figure 2). While 
RRMS is characterized by acute inflammatory attacks followed by periods of recovery, 
progression is associated by continuous loss of neurons and brain atrophy, but less 
signs of active inflammation [53]. Approximately 85% of patients initially develop a 
relapsing-remitting disease, but where a majority converts to secondary progression 
within 10-20 years. However, disease course is much dependent on age at onset 
(AAO). In late onset MS (AAO > 50), 83% of patients develops PPMS, while in young 
patients (AAO< 40) 94% initially develop RRMS and later convert to SPMS [54]. It 
could thereby be speculated if PPMS can be characterized as SPMS “amputed” from its 
relapsing remitting phase. RRMS and PPMS onset patients in average reach the same 
accumulated disability level at the same age, not after certain duration. In light of this 
fact it has been argued that MS possibly is a primary neurodegenerative disorder, and 
that inflammation is a secondary event to neurodegeneration [55].  
 
 
Figure 2: Schematic view of different disease courses in MS. A relapsing remitting onset is 
most common, and the vast majority, but not all, later enters a progressive phase, secondary 
progression. There are also onsets with primary progression with or without acute attacks. 
Primary progressive onset is more common at later age of onset, and relapsing remitting at 
younger age. 
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However, current knowledge of MS genetics argues against the hypothesis of primary 
neurodegeneration. Recent advances in the genetic analysis of risk loci in large 
materials and GWAS point out a complex genetic predisposition, with a large number 
of genes contributing to a small increase in disease risk. A majority of the identified 
risk genes are involved in regulation of immune response. Recently, a large GWAS was 
conducted identifying over 50 risk genes, where only two could be associated with a 
neurodegenerative pathway in the absence of inflammation [56]. Of all identified risk 
genes, the HLA complex shows the by far strongest association and also associates in 
virtually all genetic studies [57]. The effect within the HLA complex has during the 
past years been studied in detail and the HLA-DRB1*1501 alleles have been defined as 
the strongest genetic risk allele. Overall, the effect of genetics on disease risk is strong, 
which was first noticed by evidence of familial aggregation with 300-fold increased 
risk for monozygotic twins and 20-40 fold for biological first degree relatives but with 
no increased risk in adoptees [58]. In spite of all effort with numerous GWAS studies, 
the accumulated risk of all susceptibility loci do not explain the observed heritability. 
This missing heritability could possibly to some extent be explained by gene 
environmental interactions. An example of this is smoking, where a recent study 
identified an interaction with HLA risk alleles. Compared to non-smoker without risk 
alleles, smokers without risk alleles had an adds ratio of 1.4, non-smokers with risk 
alleles 4.9 while smokers carrying risk alleles has an odds ratio of 13.5 [59]. 
 
Severity in MS is assessed by the Multiple Sclerosis Severity Score, (MSSS). This is a 
measure based on the Expanded Disability Status Scale (EDSS), a clinical measure of 
neurological deficit [60]. EDSS together with disease duration, counted from the first 
demyelinating symptom, generates a two dimensional matrix with MSSS values based 
on observations in a large MS material and the value predicts progression and 
development of neurological deficits over time [61]. However, it does not take into 
account age of onset that previously has been described to largely affect disease course. 
Further, the accuracy of the MSSS score during the first years of the disease is less 
accurate than later. Possibly, this can be due to a large inter-individual variation in 
noticing and remembering the first demyelinating symptom. There is still no 
established risk gene for severity, and the genetics of severity likely differs from 
susceptibility. Three GWAS have addressed severity and found a number of candidates 
[62-64], but none of them has been confirmed in independent materials. 
 
There has recently been a fast development in new therapeutic strategies in MS. These 
mainly target the immune system and lower the relapse frequency in RRMS. However, 
still there is no effective drug for progressive MS. First line drugs for MS, mainly IFN-
beta, do not have a significant effect on MSSS [61]. However, more recently a new 
treatment has been developed, natalizumab, that most effectively impedes the 
transmigration of lymphocytes into the CNS and that displays a significant effect on 
disease progression and MSSS in RRMS [65, 66]. The mechanism of action for 
   13 
natalizumab also supports the nature of MS as an autoimmune disease. Longer follow 
up studies on natalizumab treatment in the years to come can reveal if there is an effect 
also on conversion to progressive disease, i.e. if highly active immunomodulatory 
treatment during the inflammatory RRMS phase can diminish the risk of later 
conversion to SPMS. A number of different drugs with immunomodulatory actions are 
currently under testing, however virtually only for RRMS. Thus, the most important 
treatment question for the future will be to develop effective treatments also for 
progressive disease. However, a necessary requisite to do so is clarify more in detail the 
underlying molecular mechanisms operating in progressive disease. 
 14 
 
   15 
4 OXIDATIVE STRESS AND NEURODEGENERATION 
 
4.1 OXIDANTS AND ANTIOXIDANTS 
Nearly all complex living organisms are dependent on oxygen for their survival. At the 
same time, oxygen is a highly reactive molecule that can cause damage to the organism 
as oxygen can form highly reactive chemical molecules, called reactive oxygen species 
(ROS). An oxidant, more often referred to as a free radical, is a molecule that lack one 
or more valence electrons and thereby attracts electrons from other molecules (since 
free electrons are almost non-existing in aqueous solutions). Therefore, there always 
needs to be a donor of the electron, the so called reductant. The electron transport 
reaction always includes these two molecules and the reactions are termed redox 
reactions. 
 
In cell biology, the two main oxidants are ROS and reactive nitrogen species. ROS is 
constantly produced in cells as part of the electron transport chain in the mitochondria 
that generates energy for the cells. It further plays an important role in defence against 
pathogens and is induced by inflammation [67]. Low levels of ROS are also a part of 
cell signalling mechanisms. Cells have developed a defence system against oxidative 
reactions by generation of molecules that can scavenge radicals and thereby prevent 
cellular damage: antioxidants. Among these are uric acid, the vitamins C and E and 
glutathione. This reaction occurs spontaneously but cells have also developed 
enzymatic reactions to enhance the efficiency of the process. Oxidative stress occurs 
when the generation of oxidants exceeds the antioxidant capacity. It is therefore, 
especially in the context of the results and discussion of this thesis, worth to emphasize 
that oxidative stress and oxidative damage are dependent on the balance between 
generation of oxidants and the cells detoxifying capacity. 
 
A main source of ROS in the CNS is from the respiratory burst system of activated 
microglia, which during inflammation release large quantities of ROS to the 
surrounding [68, 69].  
 
 
4.2 LIPID PEROXIDATION 
Free radicals can cause oxidative modification of lipids and initiate a process called 
lipid peroxidation (LPO). Polyunsaturated fatty acids (PUFA) are most easily oxidized 
due to the easily broken carbon double bonds. Therefore, saturated or monounsaturated 
fatty acids are less sensitive to oxidation. In the initiation step, a hydrogen atom is 
attracted from a lipid (LH) by a free radical, which generates a lipid radical (L●). This 
undergoes molecular rearrangements to form a conjugated diene which easily reacts 
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with oxygen, forming a lipid peroxyl radical (LOO●). This lipid hydroperoxide easily 
attracts a hydrogen atom from an adjacent lipid generating a lipid hydroperoxide 
(LOOH) and another lipid radical (L●). This way, one initiating event can lead to 
hundreds of modified lipids until the reaction is terminated (figure 3). 
 
 
 
 
Figure 3: Lipid peroxidation is a chain reaction, where one oxidized lipid generates another 
until the reaction is terminated. A single initiating event by a radical can thereby destroy 
hundreds of lipids and generate large amounts of reactive aldehyde break down products if not 
rapidly terminated. The amount of damage by reactive aldehydes in tissue will depend on 
variation at three different levels: Number of events at initiation, which is determined by 
production and detoxification of ROS; Degree of propagation where ability to terminate the 
initiated chain reactions is limiting and finally; Capacity to efficiently detoxify the produced 
aldehydes. Gsta4, which is the focus of this thesis, is involved in the last step, detoxification of 
the produced aldehydes, especially HNE, thereby preventing these from reacting with other 
molecules in the surrounding tissue. 
 
 
Since lipid peroxidation is a chain reaction it can, if not rapidly inhibited, easily destroy 
lipid rich areas such as cell membranes or myelin sheaths. In addition to destruction of 
lipid layers, cleavage of the fatty acid carbon chains of the lipid hydroperoxides results 
in generation of highly reactive aldehydes such as malondialdehyde (MDA), acrolein 
and 4-Hydroxynonenal (HNE). These have, compared to ROS, a relatively long half-
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life (HNE up to 2 minutes in tissue) and can therefore diffuse to sites distant to the 
initial oxidative event and there react to other molecules such as proteins or DNA [70]. 
HNE, which is in the focus for the results in this thesis, is a 9 carbon molecule with 
three reactive sites generated by cleavage of ω6 PUFAs and mainly reacts with the 
amino acids cysteine, histidine and lysine. The detailed chemical reactions for HNE 
generation have been reviewed elsewhere [70, 71]. Although, most studies on HNE 
focus on toxicity, it should be noticed that it also acts as an important signalling 
molecule at subcytotoxic concentrations [72].  
The CNS is particularly vulnerable to lipid peroxidation due to its high content of fat 
and particularly PUFAs. The most common PUFA in the brain is the ω3 
Dexosahexaenoic acid (DHA) followed the ω6 Arachidonic acid (ARA) [73]. Myelin, 
which surrounds the axons and is the target of the immune attacks in MS consists of 
30% protein and 70% lipids. 
 
Increased age is associated with more lipid peroxidation and suggested to be an 
important mechanism in normal aging. [74, 75]. An interesting observation is that 
animals with a longer life span seems to have lower degree of unsaturated and more 
saturated fatty acids in membranes [76, 77] . A fatty acid composition that is more 
resistant to peroxidation correlates with longevity [78-80]. Studies of C. Elegans 
transfected with mGsta4 and other HNE metabolizing GSTs show a direct correlation 
with HNE conjugating activity and lifespan [81]. Gender is possibly an important 
parameter to take into account in neuronal damage of lipid peroxidation. Males have 
been shown to have higher levels of lipid peroxidation markers after severe TBI [82], 
and this has been proposed to possibly be an effect of the antioxidant effects of 
oestrogen [83]. 
 
 
4.3 GLUTATHIONE AND GLUTATHIONE S-TRANSFERASES 
The first enzymatic defence process against oxidative stress in cells is superoxide 
dismutase, SOD, that catalyses the reaction of two superoxide molecules into oxygen 
and hydrogen peroxide (H2O2). The second step, to metabolize H2O2, uses the enzyme 
catalase or peroxidases. Among the peroxidases are glutathione peroxidases (GPxs), 
which reduces H2O2 to water by conjugation to glutathione. 
 
Glutathione is a tripeptide made up of glutamate-cysteine-glycine (Glu-Cys-Gly). This 
antioxidant is abundant in high concentrations in all cells. Most of the glutathione 
within normal cells exist in reduced form (GSH) and only a small part in an oxidized 
state (GSSH)[84]. An increased GSSH/GSH ratio is a sign of oxidative stress. Together 
with the thioredoxin system, glutathione system is considered to be the major redox 
regulating system in mammalian cells. 
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Glutathione S-Transferases (GSTs) constitute a large family of proteins that are 
divided into different classes based on their structure, but also substrate selectivity 
[85]. There are seven classes of mammalian cytosolic GSTs described, Alpha, Mu, Pi, 
Sigma, Theta, Omega, and Zeta, that generally share >40% identity within and <25% 
between subclasses [86]. Other classes are also described in non-mammalian 
organisms. GSTs are highly abundant in most mammalian cells and can compose up 
to 10% of the cytosolic proteins in some organs [87] 
 
Glutathione plays an important role for the defence against lipid peroxidation by 
terminating the chain reaction. This reducing conjunction is known to be catalysed by 
glutathione peroxidases (GPxs), which catalyse the reduction of lipid hydroperoxides, 
but also by various GSTs. GSTs also catalyse the reduction of electrophilic by products 
of lipid peroxidation, such as HNE and acrolein, by conjugation to GSH thereby 
preventing them from harmful reactions to other cellular molecules [88]. 
 
The glutathione pathway is the main cellular defence system for reducing HNE, by 
formation of stable glutathione-HNE adducts (GS-HNE), although other routes are also 
present [72]. HNE can spontaneously react to the highly abundant GSH molecules 
through so called Michael addition. However, the reaction is also catalysed by GSTs 
with an activity rate 600 times faster than the spontaneous reaction [89]. The main 
HNE reducing enzyme is Gsta4-4, which in mouse studies is indicated to make up 
approximately 70% of the reducing capacity in the brain [90]. Gsta4-4 seems to have 
evolved to reduce HNE not only by high catalytic activity, but also by having an 
exceptional resistance to HNE adduction itself [91]. Mammalian GSTs are dimeric 
proteins and named according to their subunit composition [92] The dimeric protein 
product of the gene Gsta4 is thereby named Gsta4-4. 
 
 
4.4 LIPID PEROXIDATION IN NEURODEGENERATIVE AND 
AUTOIMMUNE DISORDERS 
Oxidative stress and lipid peroxidation has been implicated as a pathogenic process of 
neurodegenerative disorders and accordingly the focus of numerous studies. The list of 
examples is long and there are also numerous reviews on the subject, for example [93, 
94]. A few examples worth to mention in relation to the data presented here are that 
HNE is considered a marker for lipid peroxidation, and has been detected in elevated 
levels in CSF of ALS [95], PD [96] and AD [97]. Further immunohistochemical 
analysis show presence of HNE in PD [98], AD [99], ALS [100] as well as in lesions of 
MS [101]. 
 
Oxidative stress and LPO are possibly not only a consequence of disease and a 
mediator of progression, but possibly also a contributory factor to disease development. 
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SOD1 variants are the main risk allele in ALS indicating the importance of oxidative 
defence status for disease development. In terms of extreme exercise being a risk factor 
for ALS it is worth to notice that studies show that high-intensity exercise induce 
oxidative stress and lipid peroxidation [102, 103], while moderate exercise can be 
regarded as an antioxidant [104]. 
 
In AD, oxidative damage is an early event in the disease course. Highest levels are seen 
initially and actually decrease with disease progression, also implying importance for 
disease development [105]. The amyloid beta peptide Aβ(1-42), found in the senile 
plaques of AD, has oxidative properties and is known to induce lipid peroxidation and 
formation of HNE [106]. Further, long term exposure to pesticides that induce 
oxidative stress is proposed to be involved in pathogenesis of PD including earlier 
onset and these are also used to induce disease in experimental models [107, 108]. 
. 
Oxidative stress and lipid peroxidation is also considered a major mechanism 
contributing to secondary degeneration after TBI [109-113], where reactive by-products 
of LPO is suggested to play a role [114]. HNE levels are elevated after TBI with a 
correlation to age in disease models [115]. Various antioxidant treatments have been 
suggested from animal experiments but so far failed to show effect on outcome in 
clinical trials in TBI [113]. 
 
Furthermore, oxidative modification of proteins has been implicated as a possible cause 
of loss of tolerance and development of autoimmune responses [116]. Smoking is a 
major risk factor in immune mediated disorder, extensively reported in RA [117-119] 
but also SLE [120, 121] and MS [59, 121]. Cigarette smoke is known to induce 
oxidative modifications to proteins and lipids [122]. Likely, increased immunogenicity 
from protein modifications by smoke is at least a contributing mechanism among many 
factors for increased risk of autoimmune disease, a notion that is supported by gene-
environment interaction of HLA and smoking [59]. 
 
In MS, smoking is not only a risk factor for disease but also seen to be associated with 
more lesions and a shorter time to transition into progressive disease phase [123]. In 
terms of MS, an autoimmune disorder with a prominent neurodegenerative facet, 
reactive aldehydes can play a role both as neurotoxins and inducers of a stronger 
autoimmune response. MDA-modification of MOG has in EAE been shown to induce a 
more aggressive disease course than unmodified MOG [124]. An interesting recent 
finding in MS with relevance to smoking, is presence of the same oxidized 
phospholipids in lesions as has been associated with inflammatory disease of the lung, 
with presence of antibodies against these in CSF and lesions [125]. Specificity of the 
OCB has been an intense focus for studies during 40 years since their discovery. 
However, recently, with the use of lipid arrays, it was reported that around 30% of the 
intrathecal antibody response is directed towards lipid epitopes [126]. Perhaps, 
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initiating events to break tolerance can occur outside the CNS, as in the lung, and later 
lead to activation of an intrathecal autoimmune response. 
 
Systemic Lupus Erythematosus (SLE) is a disorder characterized by presence of anti-
nuclear autoantibodies (ANA). The most common is against double stranded DNA 
(dsDNA) which occurs in approximately 70-80% of the patients [127]. Protein 
modification has been shown to be a major cause of autoantibody generation in SLE 
[128]. Approximately 40% of SLE patients have autoantibodies against is the 60KDa-
Ro protein [127]. Studies in a model of SLE has shown that HNE-modified Ro results 
in a stronger autoimmune response and also development of so called epitope spreading 
[129]. This is a progression mechanism where autoantibodies towards other epitopes 
than the initial immunogen are developed. In mice, presence of anti-dsDNA antibodies 
is found when immunized with HNE modified Ro but not after immunization with 
unmodified protein [130]. Further, 30-40% show antiphospholipid antibodies [131], 
which is associated with increased lipid peroxidation and epitopes of oxidized 
phospholipids [132, 133]. 
 
 
4.5 GSTA4 IN NEURODEGENERATIVE AND OTHER DISORDERS 
A possible role of Gsta4 in neurodegenerative disorders has mainly been studied in 
Parkinson’s disease. Geographic distributions of the disease has for a long time pointed 
towards important contribution of environmental factors and particularly to exposure of 
pesticides, and disease models have been developed with induction by pesticides [134]. 
The two pesticides, Maneb and Paraquat, has in combination been shown to have an 
effect on Gsta4 expression after long term exposure [135]. Low dose ip-injection of 
Paraqaut significantly has a stronger life shortening effect in Gsta4 knock-out mice 
compared to controls [90]. Pesticides are known to induce oxidative stress and GST 
activity [136]. A small association study between Gsta4 and Parkinson failed to show 
any association, but only included 60 PD and 60 Healthy controls [137]. 
 
Further, SOD1 knockout mice, used as a model of ALS, show a normal development 
up to a certain age. Expression profiling has revealed that these young mice have one 
particularly strongly up regulated gene, Gsta4, likely as a compensatory mechanism 
[138]. In the same way, Gsta4 knock-out mice activates compensatory mechanisms 
[139, 140], indicating a complex regulation of total antioxidant capacity. 
 
Higher expression of Gsta4 has been noted in key brain areas for alcohol prediction in 
alcohol preferring rats, which also show a longer expected life span [141]. A common 
link is the enzyme aldehyde dehydrogenase, which is as important enzyme in 
breakdown of alcohol but that also exerts a substantial catalytic activity against HNE 
   21 
[142, 143]. Double knock-out mice for Aldh1 and Aldh2, present in dopamine neurons, 
show age dependent motor deficits, and increased HNE levels [144]. 
 
A recent study with a forward genetic approach very similar to the studies of this thesis, 
pinpoint Gsta4 as a susceptibility gene for non-melanoma skin cancer [145]. This 
mouse study also uses global expression gene profiling together with congenic strains, 
and identify expression differences in Gsta4 as underlying the difference in melanoma 
susceptibility. Genetic variation is here also associated to human case/control data set. 
Gsta4 has also been shown to be strongly up regulated in keratinocytes upon UVB 
irradiation as a defence against oxidative stress [146, 147].  
 
Finally, there are several in vitro studies showing that overexpression of Gsta4 protects 
cells from oxidative and HNE induced injury [148, 149]. Altogether, previous 
published data points towards Gsta4 activity as an important parameter for cell survival 
under conditions of oxidative stress. The forward genetics approach in this thesis, 
pinpointing Gsta4 levels, as a main determinant of differential nerve cell survival 
between rat strains further strengthens this notion. Further studies, both genetic and 
mechanistic, will reveal if there is common variation in Gsta4 activity that is of 
pathogenic importance in human neurodegenerative disorders.  
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5 METHODOLOGY 
 
5.1 EXPERIMENTAL MODELS 
Disease models have been developed for a number of disorders and enable both genetic 
and mechanistic studies that are not possible to conduct in human disease. A main 
advantage is the possibility to reduce sources of variation by standardized induction 
protocols, control environmental factors and exclusion of factors that are not part of the 
hypothesis. Further, disease models enable, at least in theory, unlimited sample size 
under these conditions. 
 
All animal models have been performed in a standardized manner under deep 
anaesthesia with isoflurane.  
 
 
5.1.1 VRA, Ventral Root Avulsion 
Ventral root avulsion is a nerve injury model where lumbar ventral roots, containing 
axons from motoneurons within the ventral horn, are detached on the border between 
the CNS [150]. This results in activation of a local inflammatory response, with 
activation of microglia and astrocytes, infiltration of T-cells and a retrograde 
degeneration of motoneurons. Neuronal death starts to be detectable approximately one 
week after injury and most motoneurons dies during the second and third postoperative 
weeks [151]. Two of the main advantages with this model are that it is highly 
reproducible with a low degree of inter-individual variation and that it causes a minimal 
damage to the blood brain barrier, thereby mainly affecting local reactions within the 
CNS. 
 
Figure 4: Schematic overview of VRA. Ventral roots L3-L5 are avulsed leading to 
degeneration of motoneurons in the ipsi-lateral quadrant, activation of glia and formation of 
scar tissue. The micrograph to the right depicts a Cresyl violet staining from a DA rat 21 days 
post injury with a substantial neuronal loss in the ipsilateral side. The picture further shows the 
piece of the spinal cord cut out and used for expression analysis with removal of scar tissue. 
 24 
 
After VRA, spinal cord has been collected and further analysed for disease markers at 
different time points after injury. For neuronal counts, spinal cord has been collected 21 
days post injury when number of surviving motoneurons has stabilized. Neurons have 
been stained with Cresyl Violet and relative numbers achieved by counts on the injured 
side using the contralateral side as internal control. Sections have also been used for 
immunohistochemical analysis with antibodies. In general, two segments (L4-L5) have 
been used for histology. Tissue has also been collected for expression studies 5 days 
post injury, and then mostly the L3 segment. In this case, only the ipsilateral quadrant 
of the segment has been saved with careful removal of scar tissue (Figure 4).  
 
 
5.1.2 TBI, Traumatic Brain Injury 
The variation in traumatic injuries is extremely large where no injury is exactly similar 
to another. A model is therefore very valuable for studies of genetic impact on the 
outcome. There are many models for different types of TBI such as weight drop, 
controlled cortical and fluid percussion injury for contusions, a model for diffuse 
axonal injury, blast injury etc. In the model used in this thesis, we have induced 
contusion with a weight drop model [152]. In this model a craniotomy is performed 2.3 
mm lateral and 3 mm behind the bregma with great care not to damage the dura. A rod 
is placed on the exposed dura and a 24gr weight is allowed to fall on the rod from 70 
mm height and compress the tissue 3mm. In this way a standardized parietal contusion 
is achieved while the animals do not present any discernible clinical symptoms. The 
weight drop injury model has been extensively studied with regards to 
pathophysiological processes after TBI such as inflammation, oxidative stress and 
apoptosis [153-155]. 
  
The search for biomarkers in the serum or CSF of patients with TBI could serve both as 
a diagnostic and prognostic tool and also help us monitor a specific pathophysiological 
mechanism. Indeed, serum and CSF S100b, an astrocytic protein, has prognostic value 
in human TBI and serves as a severity marker. With regards to our congenic and Gsta4, 
which detoxifies HNE we wanted therefore to measure markers for neuronal injury and 
ideally HNE adducts in the CSF of animal TBI. We therefore obtained CSF from rats 
after TBI. For this purpose, a technique to collect CSF post mortem in the rat was 
established, where a 23G butterfly needle is used and the plastic cover is cut to expose 
3-4 mm of the needle tip. A stereotaxic frame is used and the rat is shaved over the 
occipital crest, where after the needle is inserted into the medullary cistern and 
approximately 100uL of CSF is drawn. Only clear CSF, free from sign of blood 
contamination has been used for analysis. 
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5.1.3 EAE, Experimental Autoimmune Encephalomyelitis 
EAE is a model of MS where an autoimmune reaction, with demyelinating lesions, is 
caused by immunization with CNS myelin antigens in combination with adjuvants. The 
CNS antigens can be composed of whole spinal cord homogenates, myelin or specific 
myelin proteins. Disease could also be elicited with transfer of myelin specific T-cells 
[156]. With the use of different antigens, immunization protocols and genetic 
background, varying features and types of MS can be mimicked.  
 
In paper IV of this thesis EAE has been induced with myelin oligodendrocyte 
glycoprotein (MOG), a small protein exposed on the surface of the myelin sheets. This 
result in a disease onset 10-14 days post-immunization and a relapsing-remitting 
disease type with many characteristics similar to MS disease course [157]. The rats are 
scored daily for clinical symptoms up to maximum 60 days post injury. Also here, the 
same technique to take CSF as applied in the TBI model has been used. Various CSF 
parameters are important diagnostic tools in MS and CSF from EAE rats therefore 
enable evaluation of known MS markers. Although MOG-EAE is considered to be the 
best model for MS it still has clear differences to human disease. One important, with 
respect to the data presented here, is that it is an acute disease which is followed only 
for approximately one month and therefore better reflects the molecular mechanisms of 
an acute inflammatory attack/relapse rather than the long term progression of MS. 
 
 
5.2 GENETIC ANALYSIS IN LABORATORY ANIMALS 
Genetic studies in laboratory animals make use of inbred strains, which are 
homozygotes at each locus in the genome. A strain is considered inbred after at least 20 
generations of brother/sister mating. Around 1910 inbreeding of rat and mouse strains 
was initiated in different labs and many of these early strains are now among the most 
widespread in laboratories around the world, for example the Wistar rat and the C57 
family of mouse strains. By the use of more than one inbred strain with different 
response to the model, average outcome values of groups can be obtained in order to 
evaluate pure genetic effect without other influences. This is referred to as the 
relationship between genotype and phenotype, and the terms were first defined by the 
famous Danish botanist Wilhelm Johansen from his studies of beans 1903 [158].  
 
5.2.1 Inbred rat strains 
In the studies presented here two different rat strains and crosses of these are described, 
Dark Agouti (DA) and Piebald Virol Glaxo (PVG). DA is widely used in 
immunological research, since it is susceptible to autoimmune diseases such as arthritis 
and EAE. DA is also highly susceptible in VRA, where it has a high degree of neuronal 
cell death, stronger activation of glial cells with high expression of MHC class II and 
high degree of infiltrating T-cells. PVG, in contrast, is more resistant to EAE (although 
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it is a dose threshold effect) and arthritis, and shows lower local inflammatory response 
and better nerve cell survival after VRA. PVG is somewhat larger than DA, but the 
phenotypic effects on the above mentioned parameters are not dependent on size.  
 
 
5.2.2 Crosses 
Crossing strains result in recombination between chromosomes and thereby random 
fragmentation of the inbred strains chromosomes. Crossing two strains creates an F1 
generation where all individuals are identical and heterozygotes at all loci. However, 
subsequent crossing of the F1 generation will result in an F2 intercross where each 
individual has a unique combination of alleles from the donor strains. On average, at 
each locus, 25% will be homozygote for strain A alleles, 50% heterozygotes and 25% 
homozygotes for allele B. Since recombinations only occur at 1-2 places on each 
chromosome, the fragments are large. Continuous crossing of F2 individuals with 
controlled random mating of at least 100 individuals will create offspring that 
accumulate more and more recombinations for each generation. This type of cross, 
termed advanced intercross line (AIL), thereby give a better resolution in genetic 
mapping [159]. An alternative approach is to backcross the F1 animals with one of the 
initial inbreds, creating only individuals homozygote for the backcrossed strain and 
heterozygotes. Backcrosses (BC) are particularly useful for studying so called heterosis 
effects, where heterozygotes display the strongest phenotype. A schematic view of 
breeding strategies is depicted below in figure 5. 
 
 
5.2.3 Congenic strains 
In congenic strains, a size limited fragment from one strain is introgressed on the 
genetic background of the other strain. As in a BC, a F1 generation animal is 
backcrossed to the strain that should be the background strain. The progeny is then 
genotyped and an animal with the desired genetic fragment is backcrossed again to the 
background strain. This is continued for at least 10 generations after which only 
approximately 0.1% of background is left, since only half of the background on average 
will be transferred for each generation (0.5
10  
< 0.001). An alternative is the speed-
congenic approach, where the background is genotyped in each generation. On average 
50% background genome will persist, but follow a normal distribution with individuals 
displaying between 30 and 70% background. Offspring with lowest level of 
background but with preservation of the desired fragment is selected for further 
backcrossing [160]. By this approach fewer generations are required to obtain the same 
low level of background as for traditionally bred congenics, but it is more labour 
intense in terms of genotyping effort.  
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Figure 5: Breeding scheme for different mapping approaches as described in the text. Two 
different strains are crossed and generate an F1 generation. Another generation of intercrossing 
of F1 individuals create an F2 that further can be intercrossed to generate more recombination 
in an AIL. F1 generation can also be backcrossed to either of the two initial strains to generate a 
BC. Further backcrossing with positive selection for genomic region of interest creates a 
congenic line.  
 
 
In contrast to knock out strains that completely lack expression of a gene, congenic 
animals in most cases better reflect human disease, where total absence only occur in 
rare cases but variation in expression levels and function is more common. However, a 
drawback with the congenic approach is that it is rare to get down to single gene 
congenics. This requires very large sample size of backcrossing and definitely a fair bit 
of good luck. The result is that the fragment often contains at least a handful of genes 
that all possibly could affect the studied phenotype. 
 
 
5.3 ANALYSIS OF GENOTYPE VERSUS PHENOTYPE 
A genetic marker is a common variation in the genome that differs between individuals. 
The rat studies have used microsatellite markers, which is tandem repeats of 2-6 base 
pairs. By polymerase chain reaction, PCR, the genomic fragment of interest is 
amplified and the size of the amplified fragment is determined by electrophoresis. The 
human data make use of single nucleotide polymorphisms, SNPs. These are single base 
pairs in the genetic code A/T/G/C that are substituted to another base. Genetic markers 
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occur frequently in the genome with microsatellite markers approximately 1 in 
14 000bp [161] and SNPs 1 for every 900bp [162]. SNPs thereby enable extremely 
dense genetic maps. 
 
There are two main approaches in identifying risk genes, linkage and association, that 
are described further below. In animal studies, identification of a single candidate gene 
mostly relies on multiple strategies such as linkage, overlapping congenic strains and 
expression analysis (figure 6). 
 
 
5.3.1 Linkage analysis 
In linkage analysis, families are studied over generations in order to find genetic 
markers that co segregate with the studied trait within the family. Thereby certain parts 
of the genome can be linked to the observed trait. Since all individuals within a study 
have to be related the number of samples in the studies is limited. Given the limited 
sample number, linkage analysis requires mutations with high penetrance. Therefore, 
this methodology has mainly been successful in finding monogenic mendelian traits. 
Examples of successful linkage analysis are Huntington’s disease [163], cystic 
fibrosis[164, 165] and breast cancer [166], but there are also examples in complex 
disease such as APOE in AD [167, 168]. 
 
Finding risk genes in experimental populations generally start with linkage analysis in 
an F2 intercross. Since the inbred rats are identical in their genome, a theoretically 
unlimited sized family can be created already in the second generation, largely 
improving the power to detect gene regions. Larger sample size will enhance the 
chance to detect traits with lower penetrance and also increase the total amount of 
recombination, enabling detection of a narrower region. An identified gene region that 
regulates the studied phenotype is called a quantitative trait locus, QTL. The VRA1 
QTL regulating neurodegeneration after VRA that has been investigated here was 
initially detected in an F2 intercross between DA and PVG [169] with interval 
mapping. Interval mapping was first described by Lander and Botstein in 1989 [170] 
and is a principle where multiple markers are analysed at the same time and the 
genotypes between markers are simulated based on recombination frequencies. 
 
The result of the linkage analysis is the likelihood that the trait pattern is linked to the 
genotype at the genomic position. This is often presented as the logarithm of odds, 
LOD. This score represents the likelihood of presence of a QTL versus the likelihood 
of no QTL, as a logarithm with the base of 10. This implies that with a LOD score of 3, 
the presence of a QTL is 1000 times more likely than no QTL. Likelihood ratio score 
(LRS) is also sometimes also used and is directly convertible to LOD, where LOD = 
LRS/4.61. In general, LOD scores above 3.3 are considered to be of significance in 
experimental crosses [171]. Empirical significance levels for a certain phenotype can 
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also be calculated by permutation tests where the data is randomized and analysed 
multiple times (generally at least 10 000) and X% significance level corresponds to a 
genome wide lower LOD score in 100-X out of 100 simulations [172]. 
 
In order to establish the genomic size of the QTL a confidence interval (CI) is 
determined. There are several different methods to establish the length and commonly 
used is the LOD drop method. A LOD drop of 1.5 is generally considered to 
correspond to a 95% confidence interval but sometimes, especially in AILs, the 
stricter1.8 is used [173, 174]. This has been used in paper one together with linkage 
analysis with the software R/QTL [175].  
 
 
 
 
  
 
5.3.2 eQTL mapping 
In paper II we make use of expression QTL (eQTL) mapping to detect candidate genes. 
An expression QTL is basically a region that regulates gene expression, rather than 
disease phenotype. However, eQTLs and a disease QTL that co-localize to the same 
marker can possibly link disease to expression pattern [176].  
 
The rapid development of chip based screening techniques in the last decade has 
enabled the possibility to study the whole transcriptome in a tissue, so called global 
gene expression profiling. By combining global expression profiling with linkage 
analysis, all expressed genes are checked for linkage to all genotyped markers in the 
genome. This generates a two dimensional matrix with data of transcripts mapping to 
any or multiple locations in the genome.  
 
eQTLs are divided into cis- or trans-acting QTLs. A cis-acting QTL is defined as 
expression regulated from the same position as the gene is located in the genome. This 
could from example be explained by differences in promoter sequence. A trans-
LO
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Figure 6: Principle of 
identifying candidate genes in 
experimental population. Solid 
line depicts LOD score from an 
F2 intercross with large CI. 
Dashed line shows how the 
fragment is reduced with an 
AIL. Further, overlapping 
congenic fragments (white 
fragments with phenotypic 
effect, dashed without) further 
reduce the interval obtained by 
the AIL to a more narrow region 
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regulated QTL maps to a position distant to the location of the gene. A large group of 
trans-regulated transcripts at a marker, trans-cluster, could for example be explained by 
differences in a transcription factor. Extremely generalized, one can state that a cis 
acting QTL is likely to be the causative gene, while trans-regulated transcripts are 
likely to be a consequence of the cis-regulated gene and can give important information 
about function of the cis-regulated gene. Of course in reality it is often more complex 
and more factors need to be taken into account that however will not be discussed 
further here. 
 
 
5.3.3 Association study 
The second approach is association, where groups of individuals are not genetically 
related is evaluated. Simply, allele frequencies are compared between two groups and if 
an allele is significantly more common in one group, this variant is considered to be 
associated with the trait. Association studies are generally more successful than linkage 
studies at finding genes variants with low penetrance, as most often is the case in 
complex disease. Since very large sample cohorts can be collected, which are not 
achievable in family studies, it becomes possible to detect a small overrepresentation in 
a group with statistical significance.  
 
The last decade, with the development of better genotyping techniques there has been 
an increasing number of large scans in various complex diseases where SNPs across the 
whole genome are scanned for a particular trait, so called genome wide association 
studies (GWAS). These are most often case/control studies where large sample sizes 
are used that enables detection of risk genes that contributes with a small increase in 
risk of developing a certain disease. The advantage of these studies is that this is an 
unbiased approach in search for genes without the use of previous knowledge that 
enables detection of new genes and mechanisms not previously associated to a certain 
disease. However, this also results in a large number of independent tests which raise 
the threshold level for significance a lot because of correction for multiple testing. In 
addition, GWAS studies have mostly been conducted with the hypothesis that a 
common disease also is caused by a common gene variant. Therefore, the chips used 
for SNP typing almost entirely include SNPs with a fairly high minor allele frequency. 
Last, it should also be noticed that GWAS rarely have analysed haplotypes and all these 
factors can possibly lead to that existing associations have not been detected. 
 
A large number of risk genes, all with a small contribution to the overall risk, have 
today been detected in various complex disorders with numerous GWAS. However, the 
sum of all these risk factors does not by far reach the observed heritability seen in 
familial studies. This discrepancy is often referred to as the missing heritability and a 
number of sources have been proposed [177]. One is large contribution of many rare 
gene variants in the population. Common gene variants, used in association, are 
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variations with long history which are widespread in the population. However, in each 
generation an estimated 175 new gene variants arise, where different rare variants can 
have a large effect at individual level on a common disease, but cannot be detected in 
association studies because of lack of linkage disequilibrium (LD) [178]. Another is 
presence of gene-gene or gene-environmental interactions that, as discussed in the 
introduction of the threshold model, means that total risk is not additive to individual 
risk factors but rather multiplicative. A third reason could also be over estimation of the 
heritability in the first place [179]. 
 
In paper IV, an association study to MS for GSTA4 gene variants has been conducted 
with 9 SNPs covering the genetic variation in the GSTA4 gene. Coverage is calculated 
based on LD for SNPs generated in large reference materials which are available in the 
HapMap project for various populations. Frequencies from the Central European 
(CEU) population group have been used for this project in order to represent the 
analysed material. If two SNPS show high degree of LD, this implies that their 
distribution differs from what can be expected by chance because these are inherited 
together. This is referred to as tagging SNPs, where a tagging SNP can be expected to 
reflect the genotype also for many other SNPs in the region. 
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6 RESULTS AND DISCUSSION 
 
6.1 ISOLATION OF A SMALL GENETIC FRAGMENT AFFECTING 
NEURODEGENERATION (PAPER I) 
Previous work on neurodegeneration in different inbred rat strains had among the tested 
strains identified DA and PVG as displaying the least and highest percentage of 
surviving motoneurons after VRA, with 26% and 50% survival, respectively [151]. To 
identify possible regulatory regions for this trait a F2 intercross between DAxPVG had 
been set up with 186 rats and phenotyped for inflammatory markers and 
neurodegeneration [169]. This study identified two gene regions affecting 
neurodegeneration; VRA1 on chromosome 8 with a significant linkage peak and a less 
strong effect on chromosome 5, VRA2, with a suggestive linkage. 
 
In paper I, we initially introgressed a genetic fragment with the size of the confidence 
interval of VRA1 from the less susceptible strain PVG onto DA background. Further 
this fragment was split up into the three recombinants R1, R2 and R3, covering 
different parts of the interval. The congenic rats were bred with traditional approach 
and with extensive recombinant breeding the number of backcrosses widely exceeds 
the minimum level of 10 generations. The three recombinant strains were tested for 
neuronal survival and, indeed, the protective effect previously seen in the F2 was 
reproduced in the congenic strains R1 and R3 but not R2. This reduced the VRA1 QTL 
to 9 Mb with 45 protein coding genes located in the smaller R3 fragment. In addition, a 
reciprocal congenic with susceptible fragment on resistant background was bred. This 
strain displayed significantly lower survival rate compared to the resistant PVG strain, 
but still better than the susceptible DA strain. Altogether, this confirms the findings 
from previous F2 intercross of gene region with a significant effect on nerve cell 
survival, but does not identify the exact gene.  
 
Subsequently, two advanced intercross lines (AIL) of 8
th
 and 10
th
 generations, 
previously used for fine mapping of a MHC class II effect [180], were used to 
reproduce and fine map the linkage. The genetic effect of VRA1 was reproduced in both 
AILs, but only just above significance level obtained by permutation test. In general, 
the better genetic resolution in an AIL has the cost of lower power [181], which implies 
that a somewhat larger population size is needed. Therefore, a combined analysis of 
both crosses was conducted which increased the linkage peak significantly and thereby 
also reduced the confidence interval. However, the confidence interval did not reduce 
the interval further than the smallest congenic, R3, and thereby did not decrease the 
number of candidate genes, but nevertheless gives further evidence for the importance 
of the genetic region by providing independent replication. 
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In addition, the suggestive QTL VRA2 was also analysed in the AILs. This QTL was 
reproduced in the larger G10 material, but not in G8. However, a multiple QTL model 
in G10 for VRA1 and VRA2 reveals a highly significant additive effect of both QTL. No 
such results were obtained by similar analysis in G8. It is likely that the penetrance of 
the VRA2 locus is smaller than for VRA1 and thereby too low to be significantly linked 
with a population of the given size. However, the effect was not present at any level in 
the G8 cohort and a combined cross analysis did not increase the significance. Another 
possibility is also a more complex pathway that requires more factors of closely related 
genes that might not be inherited together as often in an AIL as in an F2. A two 
dimensional scan could not detect any significant interaction, but it cannot be excluded 
this is due to low power. Neuronal counts in the crosses are also performed at day 14, 
as a compromise to enable studies of both neurodegeneration and inflammation in the 
same material. A later timer point, where the difference between the strains is stronger 
would perhaps also have increased the significance in the genetic mapping. 
  
With these data I conclude that VRA1 indeed is a region with high significance for 
nerve cell survival after injury and that VRA2 still is regarded as a region of suggestive 
importance.  
 
 
6.2 GETTING DOWN TO SINGLE GENE LEVEL, GSTA4 AS A LIKELY 
CANDIDATE (PAPER II AND III) 
The ultimate proof that a single gene underlies a trait is to demonstrate an effect in a 
single gene congenic. However, it is extremely rare to get down to single gene level 
and most often there is a set of genes were the likely candidate has to be identified by a 
series of indications pointing towards the mechanism. In paper II, we present a 
recombinant of the R3 strain, denoted R5, which reduce the previously reported 
fragment with an additional 3 Mb, down to 6 Mb and containing 35 protein coding 
genes. 
 
In an effort to find genes underlying various traits studied in the VRA model an F2 
intercross between DA and PVG was set up and material collected 5 days post injury 
for global expression gene profiling. This is approximately the time point just prior to 
when the motoneurons start to degenerate [182]. The time point was chosen to capture 
molecular events that determine the fate of nerve cells. At the later time points, 14 days, 
used in previous intercrosses most of the neurons are already gone, which may distort 
the molecular pattern underlying the variation. For expression profiling, the L4 segment 
was used and mRNA extracted to use with the Affymetrix Rat Gene 1.0 ST Array 
which contains more than 27 000 gene-level probe sets. 
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eQTL mapping, where all expressed transcripts are mapped to all genotyped markers in 
the genome, revealed only one strong cis-regulated gene within the R5 congenic 
fragment: Gsta4. In general, cis-regulated genes are likely candidate genes for a trait, 
while all trans-regulated transcripts might give important insights into mechanisms 
affected by the QTL and underlying genetic variation. There are four other cis-
regulated genes on the two markers analysed in VRA1. However, all displaying much 
lower p-values and none actually residing within the R5 fragment.  
 
Among the trans-regulated transcripts found in VRA1, many are genes with a link to 
neurodegeneration. Among the most striking is probably Dao, D-amino acid oxidase, 
with lower expression in the DA homozygotes, recently associated to familial ALS and 
the pathogenesis of motoneuron death in both mutant Dao and mSOD1 mice [183, 
184]. In terms of oxidative stress, the trans-regulated transcript Duox1 is also of 
interest, since it is one of the NOX-enzymes, highly specialized in generating H2O2 on 
the cell surface. [185]. It is known to be induced by pro-inflammatory molecules and 
supposed to play an important role in various states of chronic inflammation [67].  
 
Other genes with strong trans-regulation are Tap2, involved in antigen presentation and 
associated with SLE [186]. Ccl2, a pro-inflammatory chemokine reported to have dual 
effects with regard to neurodegeneration [187-189], Ucn, a protective neuropeptide that 
function to regulate stress response [190, 191], Tmod2 that is highly expressed in 
neurons and involved in synaptic plasticity [192] and Cyp39a1 involved in cholesterol 
metabolism with link to neurodegeneration [193]. A gene that possibly could be related 
to Gsta4 is Gclc, which is located as the first gene in the R3 fragment. The protein is 
involved in a rate limiting step of glutathione synthesis, and regulated by feedback 
regulation based on glutathione levels [194]. However, Gclc does not seem to map to 
the VRA1 region. 
 
A custom made antibody shows that Gsta4 protein in the CNS is mainly located within 
neurons. No commercial antibody towards rat Gsta4 was available, as was data on 
cellular localization of Gsta4 in CNS. Rat studies dating 20 years back indicated that 
Gsta4 was mainly located in astrocytes and blood vessels [195], while human stainings 
have been reported for blood vessels and neurons [196]. However, here we provide data 
clearly showing that Gsta4 mainly is a neuronal protein within the CNS (Figure 7). This 
data will also be of importance for interpretation of other rat studies on Gsta4. 
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Figure 7: Micrographs of the ventral horn in rat stained with anti Gsta4 (red) and NeuN 
(green). NeuN is a neuronal marker and the mid picture clearly depicts the large motoneurons 
located in the ventral horn. Gsta4 staining is strong in the motoneurons, but also present in other 
neurons. In paper IV, micrographs with higher magnification of motoneurons are shown. 
 
 
To further investigate the role of Gsta4 in neurodegeneration, the R5 congenic was 
tested in a in the TBI model. Importantly, global expression profiling in DA and PVG 
after TBI shows that glutathione metabolism is the strongest regulated pathway 
between the strains. The results from TBI clearly showed that Gsta4 has an effect on 
neuronal survival also after TBI. As after VRA, the R5 strain has a substantially better 
neuronal survival after TBI. Consistent with expression levels in spinal cord, brain 
tissue show similar levels of Gsta4 expression in R5 and PVG, but substantially lower 
levels in DA. Both in spinal cord and brain tissue, western blot analysis showed that 
expression differences translate into protein levels. This is important since it is the 
protein levels in the cells that affect enzymatic activity, not mRNA. This shows that the 
mechanism is of importance also for neuronal survival in trauma and therefore likely 
represents a general mechanism of importance for acute nerve injury. 
 
Further, injection of HNE directly into the brain showed neurons that positively stain 
for HNE and a stronger up-regulation of Gsta4 in R5 compared to DA. In particular, 
CA1 neurons of the hippocampus (located just under the site of injection) showed a 
strong up-regulation of Gsta4. Interestingly, these neurons are sensitive to delayed 
neuronal death in a model of cerebral ischemia, where they also stain HNE-positive 
[197]. We also showed co-staining of HNE and Tunel-positive nuclei indicating an in 
vivo role for HNE in apoptosis. In addition, levels of neurofilament light, a CSF marker 
for axonal injury, was also lower in the congenic compared to DA after HNE injection. 
Together, data point towards Gsta4 variation as being a potential mechanism of general 
relevance for neuronal survival resilience in a variety of acute conditions.  
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6.3 THE MECHANISM IN HUMAN DISEASE, RELEVANCE FOR DISEASE 
SEVERITY IN MS? (PAPER IV) 
Given the data from preceding papers, possibly GSTA4 could be of importance also for 
neurodegeneration occurring in MS. As mentioned earlier, MS is primarily an 
autoimmune disease, however, with neurodegeneration as a feature of high importance 
for disease severity and disability. Since GSTA4 in the CNS is mainly expressed by and 
located in neurons, expression or protein levels in human samples has not been possible 
to study.  
 
First, we here conduced three different EAE experiments with DA and the congenic R5 
strain. The first experiment, with milder induction protocol, showed a tendency towards 
lower disease activity in the congenic. Given the rather low number of individuals the 
difference was not statistically significant. Experiments 2 and 3 with stronger induction 
protocol failed to identify any difference in clinical score between the strains. The 
degree of difference in neuronal survival seen in VRA and TBI, if present to the same 
extent in EAE, can be difficult to detect with the rather insensitive clinical score scale 
used in EAE. Neuronal counts are much more complicated in EAE, since sites of 
lesions will differ between rats, and a certain limited area cannot be validated by its 
own. It is possible that difference in neuronal susceptibility is too small to be picked up 
with the clinical score in EAE that is affected by many more factors than only 
neurodegeneration. In addition, the sources of variation are larger in EAE compared to 
the nerve injury models. 
 
To evaluate disease severity by other means than clinical score, measurable markers as 
antibody titres were used. Possibly increased tissue damage could lead to more 
autoantigens being released and a stronger immune response. Indeed, we found a 
significant difference in antibody titres towards neurofascin in CSF between the strains. 
Neurofascin is a protein that exists in two isoforms, located in myelin and myelinated 
axons respectively. Injection of neurofascin antibodies in adoptive transfer has 
previously been shown to exacerbate EAE and further elevated antibody titres have 
been shown in approximately 20% of MS patients, particularly in progressive disease 
[198]. A similar pattern as seen in MS, with a subgroup showing highly elevated CSF 
titre, is seen in the MOG-EAE experiment in paper IV. Notably, all rats with highly 
elevated levels all belong to the DA group that has more neuronal loss in VRA and 
TBI. There is also somewhat higher total IgG-titres in CSF and anti-MOG titres in 
serum of DA rats. 
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Figure 8:  (Right) Anti-neurofascin antibodies in MS show high levels in a subpopulation of 
individuals and higher titres is especially seen in progressive disease (MS-CP)[199]. Reprinted 
with permission from J Exp Med. (Left) Results from anti-neurofascin titres in rat CSF after 
EAE show a similar pattern with a part of the individuals displaying high titres. Notably, all rats 
with highly elevated titres belong to the DA group. 
 
 
This led to the design of an association study between various MS parameters and 
GSTA4 genotype in a large case/control material. Genotype was tested for association 
to case/control as well as MSSS, a severity score, and intrathecal antibody production. 
As expected from the size of the material, there was no strong association. However, 
suggestive associations to one SNP for IgG-index/presence of OCB and another for 
MSSS-score were detected. A haplotype showed a somewhat stronger association for 
MSSS score. Unfortunately, no pure measurement of neurodegeneration, such as for 
example a reliable biomarker, could be assessed since that type of information is not 
available. The ultimate data would be MRI estimates of brain grey matter atrophy, 
which likely would best represent degree of neuronal loss. However, no such material 
is available at present time.  
 
A small Elisa experiment on CSF from MS patients and ONDs (data not included in the 
manuscript) showed no difference in average levels of GSTA4, but a large degree of 
variation within both groups. Since the hypothesis of variable sensitivity to HNE due to 
GSTA4 levels concerns levels within CNS neurons, expression analysis in human 
samples versus healthy controls is not possible. CSF might be a good way to depict 
CNS protein levels, and the preliminary data indicate a large variation. Inter-individual 
variation in human samples have also been found in hepatocytes [196]. However, 
interpretation of GSTA4 levels in CSF is unclear, since there is no data on extracellular 
GSTA4 in the CNS, although there are indications of a role of extracellular GSTA in 
the lung [200].  
 
   39 
A role of Gsta4 variation for disease severity in both MS and EAE must at this stage be 
considered as suggestive. In EAE, I believe that during the relatively short duration 
with an acute attack an effect of Gsta4 is likely have a low penetrance. In VRA and 
TBI, a clear difference in neuronal counts is seen with stereology based counts. 
However, this represents an experimental approach with far lower inter-individual 
variation within groups than EAE and also a much more precise measurement of 
neuronal cell death. To rule out a functional role of Gsta4 in EAE, I believe that a 
stronger down regulation, likely a knock-out rat, is necessary. 
 
In association to MS severity, a measurement that more purely depicts 
neurodegeneration, like grey matter atrophy, probably has a better chance to correlate 
to GSTA4 variation. Although, MSSS fairly well depicts disease severity and 
progression in historical cohorts, there are other factors that influence the degree of 
neurological handicap, in particular the introduction of disease modifying treatments. 
However, the association data encourage further studies on GST activity in MS with 
relation to severity and progression. The HLA-locus, known to be the main risk gene 
for disease, is also in some studies seen to influence severity [201, 202]. Perhaps 
stratification for HLA and possibly other disease loci is needed in larger materials to 
increase the penetrance for GSTA4 effect. 
 
 
6.4 THE FORWARD GENETICS APPROACH 
This study has utilized an unbiased genetic approach, often termed forward genetics, to 
identify a mechanism with biological relevance for neuronal death. The methodology 
has the advantage that it pinpoints mechanisms and can create new hypothesis not 
based on previous knowledge. This is in contrast to the hypothesis driven research, 
where a study is designed based on an assumption from previous findings and data. The 
forward genetics approach also has the advantage to study natural genetic variation, 
likely more relevant for human disease than for example a knock out approach. 
 
However, it is time consuming and also a work intense way to find a mechanism of 
relevance that does not necessarily need to be novel data. From the first publication of 
the VRA1 QTL until publication of Gsta4 as the likely underlying gene in paper II of 
this thesis, 8 years passed. This finally points towards regulation an established 
pathway for neurodegeneration. HNE toxicity has previously has been extensively 
studied in neurodegenerative disorders and in vitro experiments and found to induce 
cell death in a concentration dependent manner. Further, biochemical studies have 
identified Gsta4-4 as extremely efficient enzyme in reducing HNE, and from knock out 
studies it is also regarded as the main enzyme catalysing the reduction in the CNS.  
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However, the main finding which I have also tried to emphasize is that there is a 
natural genetic variation in this pathway that to a large extent affect neuronal survival. 
This data now encourage further studies on this variation both in experimental models 
of other neurodegenerative disorders as well in human disease. 
 
 
6.5 IS GSTA4 THE RIGHT GENE? 
The smallest congenic described still has 35 protein coding genes. Each of these genes, 
or a combination of genes, could possibly explain the increased nerve cell survival seen 
in this strain. Although extensive recombinant breeding has been conducted, a congenic 
with only one or a few genes has not been achieved. There is of course a risk that 
another gene could alone or together with Gsta4 underlie the observed effect in the 
congenic rats. Since single gene congenics are extremely rare, identifying underlying 
genes mostly has to be based on a series of indications that together makes it unlikely 
that another gene is causative. 
 
The main finding that led to the conclusion that Gsta4 is the right gene is the eQTL 
mapping results. This showed that only one cis-regulated gene exist in the congenic 
fragment. This together with the involvement in an established pathway for 
neurodegeneration, the cellular localization within neurons and a direct effect of the 
congenic on HNE-injection makes it unlikely for Gsta4 not to be of relevance for the 
trait. However, for example genetic variation that affects molecular functions and not 
expression levels in other genes could possibly have an effect that we have not 
detected. 
 
It is important to point out that formal proof requires exact definition of the genetic 
variability underlying VRA1 and ideally the development of a single gene congenic. 
Even if a knock out generally do not contribute to the finding of effect of natural 
variation, such a strain could be used here as a prof of a relation between Gsta4 and 
nerve cell survival in our models.  
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7 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
In summary, this thesis highlights that naturally occurring genetic variation in a 
population to a large extent affect the degree of neuronal cell death in the CNS. It 
further points out a certain mechanism and gene that encourage future studies. Below, I 
try to summarize the most essential findings together with my opinion on important 
future steps to further validate the relevance of this genetic variation. 
 
 Genetic mapping 
Degeneration of neurons in the CNS after injury is highly dependent on genetic factors 
and here a relationship between capacity to detoxify reactive breakdown products of 
lipid peroxidation and degree of neurodegeneration is highlighted. Gsta4 is highly 
expressed in neurons and regulated between different inbred rat strains and higher 
levels of Gsta4 is associated with better neuronal survival in experimental models. The 
effect is seen in three different crosses and reproduced in congenic strains, where the 
smallest positive fragment contains only 35 genes. 
 
Further reduction of the congenic fragment in order to get a single gene congenic only 
containing Gsta4 and no or few other genes in the fragment would be the ultimate proof 
that Gsta4 is the right gene underlying the trait. Extensive recombinant breeding has 
been done over the last years and there is now a recombinant from the R5 that further 
reduces the congenic interval by approximately 10 genes that can be used for further 
studies. Further reduction will be a very extensive work, both in terms of number of 
animals, genotyping and time, yet with unknown certainty of success. An alternative 
approach would be to make a genetically modified knockout rat; a technique that has 
been used in mice for decades but just recently has become available in this species 
[203, 204]. An approach that is considered is to create a partial knock out, where the 
levels of expression of Gsta4 could be regulated. This could prove an effect of variable 
expression level and also enable stronger down regulation than seen in DA versus R5. 
This is likely to be beneficial for the study of a Gsta4 effect in EAE where the 
phenotype is less well defined and the degree of inter-individual experimental variation 
is larger than in the neurodegenerative models. 
 
The second region previously detected to affect neurodegeneration, VRA2, is still a 
suggestive region. The eQTL mapping revealed interesting candidate genes also here, 
but data is still too speculative for publication. However, just adjacent to the G10 
intercross linkage peak, there is a cis-regulation of the gene Trp53inp1, an anti-
proliferative and pro-apoptotic gene [205] involved in p53 dependent stress response, 
that has been implicated in diabetes [206] and as a tumour suppressor [207]. It has 
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further been shown to be involved in the antioxidant role of p53 [208], and mice 
deficient in TRP53inp1 are shown to have an increased oxidative load [209]. However, 
future studies are needed to evaluate the role of VRA2 and the underlying genetic 
variance, ideally with another model with better penetrance for the effect. 
 
 The mechanism in rat studies 
The replication of an effect on neuronal survival originally observed in VRA to TBI 
indicates that this likely is a mechanism of general relevance for severity in various 
acute nerve injuries. Direct injection of HNE into the cortex is associated with lower 
degree of neuronal damage in rats displaying higher Gsta4 levels in the neurons. 
Further, a model of neuroinflammation, EAE, indicates that Gsta4 also might play a 
role for development of antibody response towards CNS autoantigens. 
 
The congenic strain described in this thesis could be used also in other models. It is 
planned to be tested in a model of Parkinson’s disease, which can provide further 
support for a general relevance of variations in this detoxification mechanism. Further, 
the fact that Gsta4 is highly expressed and located within neurons in the CNS will be of 
importance for interpretation of expression data from other studies and models. While 
most previous findings have dealt with the degree of oxidative burden and regulation of 
production of free radicals, these findings show variation in neurons ability to resist the 
same amount of oxidative burden. 
 
An important step in further studies will be to define a quantitative measure of HNE-
protein complexes, and neuronal survival, ideally under controlled equal oxidative 
insult. Likely, in vitro studies of neuronal cultures would be a favourable approach 
were neurons from DA and R5 can be directly exposed HNE and other oxidants. These 
would possibly also enable quantitative measurements of HNE-modified neuronal 
proteins in high concentration. So far we have not successfully ben able to quantify this 
given the low levels in our in vivo models. 
 
The mechanism of increased immunogenicity towards HNE modified proteins will also 
further be studied. Previous studies have shown that MDA modified MOG is more 
immunogenic and results in a more severe EAE disease course [124], and it not too 
speculative to believe that HNE-modification could have the same properties. Since 
HNE naturally modifies a wide range of proteins, an interesting approach would be 
induction of EAE with whole spinal cord, with and without in vitro modification of the 
homogenate. This would depict the wide spectrum of HNE-modified antigens that is 
likely to exist in human disease. 
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 Relevance for human disease 
An association study to severity and intrathecal antibody response in MS show that 
genetic variation in GSTA4 possibly can have an effect for disease severity. We have 
also in a small pilot test seen that there is a large variation in GSTA4 levels in CSF 
between individuals. These data encourage further investigation of a role for genetic 
variation of GSTA4 in neurodegenerative and autoimmune disorders. Several lines of 
evidence suggest that generation of reactive oxygen species is of importance in this 
context. In light of this, the notion that higher levels of Gsta4 in CNS neurons correlate 
with better survival is of high interest, since this suggests yet another level where this 
important pathway may be regulated, indicating coping capability for oxidative stress 
and lipid peroxidation by-products as a key mechanism.  
 
In terms of the combined effect of genetic risk factors for disease; my standpoint is that 
it would be of great value for understanding of disease mechanisms to evaluate 
combined effects of genetic variation in lipid peroxidation pathway. For example 
variation in SOD1 which leads to increased oxidative stress in combination with certain 
Gsta4 variants giving a low detoxifying capacity. This is an approach that should be of 
interest in large experimental populations where genetic manipulation of multiple genes 
is possible as well as for interaction analysis in human disease association studies. In 
theory, these genetic factors together would be a setting where combined effects could 
result in multiplicative disease risk as is expected for complex neurodegenerative 
disorders. 
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